Clinical Trials Logo
  1. Home
  2. Renal Failure, Chronic
  3. NCT02259296

Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure — TACTIC  

Renal Failure, Chronic Clinical Trial

Official title:
Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure

Clinical Trial Summary

The timing for arteriovenous fistula (AVF) creation and its effect on target organs in patients with chronic renal failure will be investigated by multicenter prospective cohort. Lower estimated glomerular filtration rate (eGFR) patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) and higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) will be proposed to undertake AVF creation. Maturation rate and time of AVF will be followed up in 3 months; primary and secondary patency rate of AVF, AVF construction on cardiac structure, function, encephalopathy, cerebral vascular lesions and cognitive function will be followed up in the next 2 years. This multicenter will provide evidence to develop guideline of timing for AVF creation

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02259296
Study type Interventional
Source Shanghai Changzheng Hospital
Contact Xiang Gao
Phone +862181885397
Email gaoxiang43100636@163.com
Status Not yet recruiting
Phase N/A
Start date January 2015
Completion date December 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT00259025 - Intravenous n-3 Fatty Acids and Sudden Cardiac Death in Hemodialysis Patients Phase 2
Completed NCT00176059 - Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients Phase 0
Completed NCT00438503 - Glucose in Dialysis Water in Diabetics With Chronic Renal Failure Phase 4
Completed NCT00439023 - Glucose in Dialysis Water in Non-diabetics Phase 4
Completed NCT03904836 - Tobramycin Administered at the Beginning of Dialysis Phase 1
Completed NCT00150891 - Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection N/A
Completed NCT01875523 - PK of Serelaxin in Severe Renal Impairment and ESRD Phase 1
Completed NCT00438295 - Temperature Control During Dialysis Treatment Phase 4
Terminated NCT00664066 - DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
Withdrawn NCT00262353 - Elimination of Protein-bound Uremic Retention Solutes by Prometheus Artificial Hepatic System Versus Conventional Dialysis N/A